Publications

OPAL Publications & Presentations for Reporting

**Papers from other studies approved to use the OPAL resource by QIMR Berghofer Ethic Committee.


PUBLICATIONS


2017:

Consortium papers:

Phelan CM, Kuchebaecker KB, Tyrer JP, ... Webb PM et al. Identification of twelve novel susceptibility loci for different histotypes of epithelial ovarian cancer. Nat Genet, 2017; 49(5): 680-691. https://www.ncbi.nlm.nih.gov/pubmed/28346442

Glubb DM, Johnatty SE, Quinn MCJ, ... Webb PM et al. Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci. Oncotarget, 2017; 8:64670-64684. https://www.ncbi.nlm.nih.gov/pubmed/29029385


2018:

Beesley VL, Smith DD, Nagle CM, Friedlander M, Grant P, DeFazio A, Webb PM. Coping strategies, trajectories, and their associations with patient-reported outcomes among women with ovarian cancer. Support Care Cancer. 2018; 26(12): 4133-4142. https://www.ncbi.nlm.nih.gov/pubmed/29948398

OPAL Substudies:

**Staneva AA, Gibson AF, Webb PM, Beesley VL. The Imperative for a Triumph-Over-Tragedy Story in Women's Accounts of Undergoing Chemotherapy for Ovarian Cancer. Qual Health Res. 2018;28(11):1759-1768. https://www.ncbi.nlm.nih.gov/pubmed/29938608


Consortium papers:

Lu Y, Beeghly-Fadiel A, Wu L, Guo X, Li B, Schildkraut JM, Im HK, Chen YA, Permuth JB, Reid BM, Teer JK, Moysich KB, Andrulis IL, Anton-Culver H, Arun BK, Bandera EV, ... Webb PM, Weitzel JN, Wentzensen N, White E, Wolk A, Wu AH, Yannoukakos D, Zorn KK, Gayther SA, Antoniou AC, Berchuck A, Goode EL, Chenevix-Trench G, Sellers TA, Pharoah PDP, Zheng W, Long J. A transcriptome-wide association study among 97,898 women to identify candidate susceptibility genes for epithelial ovarian cancer risk. Cancer Res. 2018; 10.1158/0008-5472.can-18-0951. https://www.ncbi.nlm.nih.gov/pubmed/30054336


2019:

OPAL Substudies:

Staneva AA, Beesley VL, Niranjan N, Gibson AF, Rowlands I, Webb PM. "I Wasn't Gonna Let It Stop Me": Exploring Women's Experiences of Getting Through Chemotherapy for Ovarian Cancer. Cancer Nursing, 2019; 42(2): e31-e38. https://www.ncbi.nlm.nih.gov/pubmed/29538021

Consortium papers:

Jiang X, Finucane HK, Schumacher FR, ... Webb PM, Chenevix-Trench G, et al. Shared heritability and functional enrichment across six solid cancers. Nat Commun, 2019; 10(1): 431. https://pubmed.ncbi.nlm.nih.gov/30683880

Minlikeeva AN, Cannioto R, Jensen A, ... Webb PM, Moysich KB. Joint exposure to smoking, excessive weight, and physical inactivity and survival of ovarian cancer patients, evidence from the Ovarian Cancer Association Consortium. Cancer Cause Control, 2019; 30(5): 537-547. https://pubmed.ncbi.nlm.nih.gov/30905014

Yang Y, Wu L, Shu X, ... Webb PM, ... Chenevix-Trench G, et al. Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. Cancer Res, 2019; 79(3): 505-517. https://pubmed.ncbi.nlm.nih.gov/30559148


2020:

Sivakumaran T, Mileshkin L, Grant P, Na L, DeFazio A, Friedlander M, Obermair A, Webb P, Au-Yeung G, the OPAL study group. Evaluating the impact of dose reductions and delays on Progression Free Survival in women with ovarian cancer treated with either three weekly or dose dense Carboplatin and Paclitaxel regimens in the national prospective OPAL cohort study. Gynecol Oncol, 2020; 158(1): 47-53. https://pubmed.ncbi.nlm.nih.gov/32381362/

Ross TL, DeFazio A, Friedlander M, Grant P, Nagle CM, Williams M, Webb PM, Beesley VL, OPAL Study Group. Insomnia and its association with quality of life in women with ovarian cancer, Gynecol Oncol, 2020; 158(3):760-768. https://pubmed.ncbi.nlm.nih.gov/32653100/

Beesley VL, Webber K, Nagle CM, DeFazio A, Obermair A, Williams M, Friedlander M, Webb PM, OPAL Study Group. When will I feel normal again? Trajectories and predictors of persistent symptoms and poor wellbeing after primary chemotherapy for ovarian cancer. Gynecol Oncol, 2020; S0090-8258(20)33664-7. https://pubmed.ncbi.nlm.nih.gov/32773150/

Hansen JM, Nagle CM, Ibiebele TI, Grant PT, Obermair A, Friedlander ML, DeFazio A, Webb PM, Ovarian Cancer Prognosis and Lifestyle Study Group. Int J Cancer, 2020; doi: 10.1002/ijc.33155. https://pubmed.ncbi.nlm.nih.gov/32542708/



ORAL PRESENTATIONS


2016:

Webb PM. Lifestyle, quality of life & survival after ovarian cancer: Ovarian Cancer Prognosis & Lifestyle Study (OPAL). Cancer Council Queensland Ovarian Cancer Forum, Brisbane, February 2016.

Beesley VL, Smith DD, De Fazio A, Obermair A, Grant P, Nagle CM, Friedlander M, Webb PM on behalf of the OPAL Study Group. Coping strategies, trajectories and their associations with patient-reported outcomes among women with ovarian cancer. Multinational Association of Supportive Care in Cancer Annual Meeting, Adelaide, Australia, June, 2016.

Webb PM. Can we improve outcomes for women with ovarian cancer? The Ovarian Cancer Prognosis and Lifestyle (OPAL) Study: goals and early results. Ovarian Cancer Australia Forum, Melbourne, December, 2016.

2017:

Minlikeeva AN, Cannioto RA, Szender JB, Mayor P, Jensen A, Kjaer SK, Webb PM, Moysich KB on behalf of the Ovarian Cancer Association Consortium. Joint exposure to smoking, excessive weight, and physical inactivity affects survival of ovarian cancer patients, evidence from the Ovarian Cancer Association Consortium. SGO, 2017.

Webb PM, Na N, Beesley V, DeFazio A, Friedlander M, Grant P, Obermair A, the OPAL Study Group. Lifestyle, side-effects and chemotherapy completion. Results from the Ovarian Cancer Prognosis and Lifestyle (OPAL) Study. Australian and New Zealand Gynaecologic Oncology Group Annual Scientific Meeting, Melbourne, April 2017.

2018:

Friedlander M, King M, Nagle C, Obermair A, Grant PT, DeFazio A, Webb PM. Getting the most out of follow?up: a prospective study using the Measure of Ovarian Symptoms and Treatment concerns (MOST) symptom index to evaluate and track adverse effects (AEs) and detect symptoms of recurrence in patients with ovarian cancer (OC) following first line chemotherapy (1LT). ANZGOG Annual Scientific Meeting, Brisbane, April, 2018.

Sivakumaran T, Mileshkin L, Grant P, Webb PM, Au-Yeung G, The Opal Study Group. Comparing the impact of dose reductions and delays on ovarian cancer patient outcomes with Three-weekly versus Dose Dense Carboplatin and Paclitaxel regimens in the national prospective OPAL cohort. ANZGOG Annual Scientific Meeting, Brisbane, April, 2018.

Webb PM, Beesley VL, DeFazio A, Obermair A, Grant PT, Nagle CM, Friedlander M, The OPAL Study Group. The hidden burden of anxiety and depression in ovarian cancer: a prospective longitudinal study from diagnosis. ANZGOG Annual Scientific Meeting, Brisbane, April, 2018.

2020:

Hansen J, Nagle CM, Ibiebele T, Webb PM for the OPAL Study Group. A healthy lifestyle and survival among women with ovarian cancer. The 3rd Victorian Cancer Survivorship Conference, Melbourne, March 2020.



POSTERS


2015:

Webber K, Friedlander ML, King MT, Webb PM for the OPAL Study Gorup. Trajectories of persistent symptoms after completion of primary treatment for ovarian cancer. European Society of Gynaecological Oncology, Nice, France, October 2015.

2018:

Beesley VL, Nagle CM, Grant PT, DeFazio A, Obermair A, Friedlander M, Webb PM, The OPAL Study Group. When will I feel normal again? Quality of life trajectories after first-line chemotherapy for ovarian cancer. ASCO Survivorship Symposium, Orlando, February 2018.

Webb PM, DeFazio A, Obermair A, Grant PT, Friedlander M, Beesley VL, Nagle CM, The OPAL Study Group. The Ovarian cancer Prognosis And Lifestyle (OPAL) Study. ASCO Survivorship Symposium, Orlando, February 2018.

Webb PM, Beesley VL, DeFazio A, Obermair A, Grant PT, Nagle CM, Friedlander M, The OPAL Study Group. The hidden burden of anxiety and depression in ovarian cancer: a prospective longitudinal study from diagnosis. ASCO Survivorship Symposium, Orlando, February 2018.

Beesley VL, Nagle CM, Grant PT, DeFazio A, Obermair A, Friedlander M, Webb PM, The OPAL Study Group. When will I feel normal again? Quality of life trajectories after first-line chemotherapy for ovarian cancer. ANZGOG Annual Meeting, Brisbane, April, 2018.

Friedlander M, DeFazio A, Obermair A, Grant PT, Beesley VL, Nagle CM, Webb PM, The OPAL Study Group. Getting the most out of follow-up: A prospective study using the Measure of Ovarian Symptoms and Treatment concerns (MOST) symptom index to evaluate and track adverse effects (AEs) and detect symptoms of recurrence in patients with ovarian cancer (OC). ASCO, Chicago, June 2018.

Sivakumaran T, Grant P, Friedlander M, Webb PM, Au-Yeung G... The OPAL Study Group. Comparing the impact of dose reductions and delays on ovarian cancer patient outcomes with three-weekly versus dose dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort. ASCO, Chicago, June 2018.

Webb PM, Beesley VL, DeFazio A, Obermair A, Grant PT, Nagle CM, Friedlander M, The OPAL Study Group. The hidden burden of anxiety and depression in ovarian cancer: a prospective study from diagnosis. ASCO, Chicago, June 2018.

2019:

Majidi A, Na R, Webb PM, OPAL Study Group. Statin use and ovarian cancer survival. Australasian Epidemiological Association Annual Meeting, Brisbane, October 2019.

Hansen JM, Nagle CM, Ibiebele TI, Webb PM, OPAL Study Group. Healthy lifestyle choices after a diagnosis of ovarian cancer may help women to improve their survival. Australasian Epidemiological Association Annual Meeting, Brisbane, October 2019.

Bookmark and Share